keyword
https://read.qxmd.com/read/25824487/activating-and-inhibitory-functions-of-wnt-%C3%AE-catenin-in-the-induction-of-cytochromes-p450-by-nuclear-receptors-in-heparg-cells
#21
JOURNAL ARTICLE
Maria Thomas, Christine Bayha, Silvia Vetter, Ute Hofmann, Michael Schwarz, Ulrich M Zanger, Albert Braeuning
The WNT/β-catenin signaling pathway has been identified as an important endogenous regulator of hepatic cytochrome P450 (P450) expression in mouse liver. In particular, it is involved in the regulation of P450 expression in response to exposure to xenobiotic agonists of the nuclear receptors constitutive androstane receptor (CAR), aryl hydrocarbon receptor (AhR), and Nrf2. To systematically elucidate the effect of the WNT/β-catenin pathway on the regulation and inducibility of major human P450 enzymes, HepaRG cells were treated with either the WNT/β-catenin signaling pathway agonist, WNT3a, or with small interfering RNA directed against β-catenin, alone or in combination with a panel of activating ligands for AhR [2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)], CAR [6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime (CITCO)], pregnane X receptor (PXR) [rifampicin], and peroxisome proliferator-activated receptor (PPAR) α [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY14,643)]...
June 2015: Molecular Pharmacology
https://read.qxmd.com/read/25652102/cyp2c19-17-affects-r-warfarin-plasma-clearance-and-warfarin-inr-dose-ratio-in-patients-on-stable-warfarin-maintenance-therapy
#22
JOURNAL ARTICLE
Ming Chang, Mao Mao Söderberg, Maria Gabriella Scordo, Gunnel Tybring, Marja-Liisa Dahl
PURPOSE: We aimed to assess the influence of CYP2C19*17 on R-warfarin clearance as well as the effect of CYP2C19, CYP2C8, CYP2C9, and VKORC1 polymorphisms together with non-genetic factors on warfarin international normalized ratio (INR)/daily dose. METHODS: One hundred fifty Caucasian Italian outpatients with data on steady-state plasma concentrations of S- and R-warfarin were genotyped for CYP2C19 (*2, *3, *4, *17), CYP2C9 (*2, *3), CYP2C8*3, and VKORC1*2. The statistical analysis was performed on the effect of genotypes/haplotypes, age, sex, and body weight on the clearance of warfarin enantiomers and dose-normalized INR...
April 2015: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/25640739/preemptive-genotyping-of-cyp2c8-and-cyp2c9-allelic-variants-involved-in-nsaids-metabolism-for-sickle-cell-disease-pain-management
#23
JOURNAL ARTICLE
Cheedy Jaja, Latanya Bowman, Leigh Wells, Niren Patel, Hongyan Xu, Matt Lyon, Abdullah Kutlar
Interindividual variability in analgesic effects of nonsteroidal anti-inflammatory drugs prescribed for sickle cell disease (SCD) pain is attributed to polymorphisms in the CYP2C8 and CYP2C9 enzymes. We described CYP2C8 and CYP2C9 genotype/phenotype profiles and frequency of emergency department (ED) visits for pain management in an African American SCD patient cohort. DNA from 165 unrelated patients was genotyped for seven CYP2C8 and 15 CYP2C9 alleles using the iPLEX ADME PGx multiplexed panel. CYP2C8*1 (0...
August 2015: Clinical and Translational Science
https://read.qxmd.com/read/25595597/a-long-standing-mystery-solved-the-formation-of-3-hydroxydesloratadine-is-catalyzed-by-cyp2c8-but-prior-glucuronidation-of-desloratadine-by-udp-glucuronosyltransferase-2b10-is-an-obligatory-requirement
#24
JOURNAL ARTICLE
Faraz Kazmi, Joanna E Barbara, Phyllis Yerino, Andrew Parkinson
Desloratadine (Clarinex), the major active metabolite of loratadine (Claritin), is a nonsedating long-lasting antihistamine that is widely used for the treatment of allergic rhinitis and chronic idiopathic urticaria. For over 20 years, it has remained a mystery as to which enzymes are responsible for the formation of 3-hydroxydesloratadine, the major active human metabolite, largely due to the inability of any in vitro system tested thus far to generate this metabolite. In this study, we demonstrated that cryopreserved human hepatocytes (CHHs) form 3-hydroxydesloratadine and its corresponding O-glucuronide...
April 2015: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://read.qxmd.com/read/25561246/inhibition-of-in-vitro-metabolism-of-testosterone-in-human-dog-and-horse-liver-microsomes-to-investigate-species-differences
#25
JOURNAL ARTICLE
Jana Zielinski, Meike Mevissen
Testosterone hydroxylation was investigated in human, canine and equine liver microsomes and in human and canine single CYPs. The contribution of the CYP families 1, 2 and 3 was studied using chemical inhibitors. Testosterone metabolites were analyzed by HPLC. The metabolites androstenedione, 6β- and 11β-hydroxytestosterone were found in microsomes of all species, but the pattern of metabolites varied within species. Androstenedione was more prominent in the animal species, and an increase over time was seen in equines...
April 2015: Toxicology in Vitro: An International Journal Published in Association with BIBRA
https://read.qxmd.com/read/25560582/association-of-cyp2c8-cyp2c9-and-cyp2j2-gene-polymorphisms-with-myocardial-infarction-in-south-indian-population
#26
JOURNAL ARTICLE
Annan Sudarsan Arun Kumar, Srinivasamurthy Suresh Kumar, Gurusamy Umamaheswaran, Ramasamy Kesavan, Jayaraman Balachandar, Chandrasekaran Adithan
BACKGROUND: Cardiovascular diseases (CVDs) are the major cause of mortality and morbidity worldwide. Myocardial infarction (MI) is a complex multi-factorial, polygenic disorder arising from an interaction between genetic makeup of individuals and various environmental factors. CYP2C8, CYP2C9 and CYP2J2 gene involved in the metabolism of arachidonic acid, generates epoxyeicosatrienoic acids (EETs) that mediate dilation of coronary arteries improving post-ischemic cardiac contractile function, reduce vascular inflammation, and increase intravascular fibrinolysis...
February 2015: Pharmacological Reports: PR
https://read.qxmd.com/read/25504632/a-multicenter-phase-i-study-of-pazopanib-in-combination-with-paclitaxel-in-first-line-treatment-of-patients-with-advanced-solid-tumors
#27
MULTICENTER STUDY
Kari L Kendra, Ruth Plummer, Ravi Salgia, Mary E R O'Brien, Elaine M Paul, A Benjamin Suttle, Natalie Compton, Chun-Fang Xu, Lone H Ottesen, Miguel A Villalona-Calero
This study was designed to evaluate the safety, pharmacokinetics, and clinical activity of pazopanib combined with paclitaxel to determine the recommended phase II dose in the first-line setting in patients with advanced solid tumors. Patients were enrolled in a 3+3 dose-escalation design to determine the maximum tolerated regimen (MTR) of once daily pazopanib plus paclitaxel administered every 3 weeks at four dose levels (DL1-4). Safety, pharmacokinetics, pharmacogenetics, and disease assessments were performed...
February 2015: Molecular Cancer Therapeutics
https://read.qxmd.com/read/25470432/metronidazole-reduces-the-expression-of-cytochrome-p450-enzymes-in-heparg-cells-and-cryopreserved-human-hepatocytes
#28
JOURNAL ARTICLE
Toshiyuki Kudo, Yumiko Endo, Rina Taguchi, Masami Yatsu, Kiyomi Ito
1. Blood levels of S-warfarin have been reported to be increased by concomitant administration of metronidazole (MTZ), an antiprotozoal imidazole derivative. 2. To elucidate the mechanism of this interaction and to identify other possible drug-drug interactions, we conducted an in vitro study with the human hepatoma HepaRG cells and cryopreserved human hepatocytes on the ability of MTZ to reduce the expression of cytochrome P450 (CYP) as well as nuclear receptors that regulate the expression of these enzymes...
May 2015: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://read.qxmd.com/read/25465228/safety-and-pharmacokinetics-of-the-cime-combination-of-drugs-and-their-metabolites-after-a-single-oral-dosing-in-healthy-volunteers
#29
JOURNAL ARTICLE
Natacha Lenuzza, Xavier Duval, Grégory Nicolas, Etienne Thévenot, Sylvie Job, Orianne Videau, Céline Narjoz, Marie-Anne Loriot, Philippe Beaune, Laurent Becquemont, France Mentré, Christian Funck-Brentano, Loubna Alavoine, Philippe Arnaud, Marcel Delaforge, Henri Bénech
This phase I, pilot clinical study was designed to evaluate the safety and the pharmacokinetic (PK) profiles of the CIME (Metabolic Identity Card) combination of ten drugs, with a view to its use as a phenotyping cocktail. Ten healthy Caucasian subjects were orally dosed with the CIME combination (caffeine-CYP1A2, repaglinide-CYP2C8, tolbutamide-CYP2C9, omeprazole-CYP2C19, dextromethorphan-CYP2D6, midazolam-CYP3A, acetaminophen-UGT1A1, 6&9 and 2B15, digoxin-P-gp, rosuvastatin-OATP1B1&3 and memantine-active renal transport)...
April 2016: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/25458605/the-genetic-variants-underlying-breast-cancer-treatment-induced-chronic-and-late-toxicities-a-systematic-review
#30
JOURNAL ARTICLE
Terence Ng, Mint Chan, Chiea Chuen Khor, Han Kiat Ho, Alexandre Chan
A systematic review was performed to describe the findings from 19 genetic association studies that have examined the genetic variants underlying four common treatment-induced chronic and late toxicities in breast cancer patients, and to evaluate the quality of reporting. Three out of 5 studies found an association between HER2 lle655Val polymorphisms and trastuzumab-induced cardiotoxicity. Two studies found a positive association between cognitive impairment and the Val allele of the COMT gene and the ε4 allele of the apolipoprotein E gene...
December 2014: Cancer Treatment Reviews
https://read.qxmd.com/read/25430798/inhibitory-effect-of-six-herbal-extracts-on-cyp2c8-enzyme-activity-in-human-liver-microsomes
#31
JOURNAL ARTICLE
Ahmed A Albassam, Mohamed-Eslam F Mohamed, Reginald F Frye
1. Herbal supplements widely used in the US were screened for the potential to inhibit CYP2C8 activity in human liver microsomes. The herbal extracts screened were garlic, echinacea, saw palmetto, valerian, black cohosh and cranberry. N-desethylamodiaquine (DEAQ) and hydroxypioglitazone metabolite formation were used as indices of CYP2C8 activity. 2. All herbal extracts showed inhibition of CYP2C8 activity for at least one of three concentrations tested. A volume per dose index (VDI) was calculated to determine the volume in which a dose should be diluted to obtain IC50 equivalent concentration...
May 2015: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://read.qxmd.com/read/25424246/drug-drug-interaction-between-losartan-and-paclitaxel-in-human-liver-microsomes-with-different-cyp2c8-genotypes
#32
JOURNAL ARTICLE
Yuji Mukai, Asuna Senda, Takaki Toda, Toru Hayakawa, Erik Eliasson, Anders Rane, Nobuo Inotsume
The cytochrome P450 (CYP) 2C8*3 allele is associated with reduced metabolic activity of paclitaxel. This study was aimed to investigate the inhibitory effect of losartan on paclitaxel metabolism in human liver microsomes (HLMs) and to determine the impact of the CYP2C8*3 polymorphism. HLMs that contained the CYP2C8*1 homozygote (HL60) or CYP2C8*3 heterozygote (HL54) genotype were used for the inhibition study. Losartan, at a concentration of 50 μmol/L, significantly inhibited paclitaxel metabolism by 29% and 57% in the HL60 (p < 0...
June 2015: Basic & Clinical Pharmacology & Toxicology
https://read.qxmd.com/read/25395831/effect-of-honokiol-on-the-induction-of-drug-metabolizing-enzymes-in-human-hepatocytes
#33
JOURNAL ARTICLE
Yong-Yeon Cho, Hyeon-Uk Jeong, Jeong-Han Kim, Hye Suk Lee
Honokiol, 2-(4-hydroxy-3-prop-2-enyl-phenyl)-4-prop-2-enyl-phenol, an active component of Magnolia officinalis and Magnolia grandiflora, exerts various pharmacological activities such as antitumorigenic, antioxidative, anti-inflammatory, neurotrophic, and antithrombotic effects. To investigate whether honokiol acts as a perpetrator in drug interactions, messenger ribonucleic acid (mRNA) levels of phase I and II drug-metabolizing enzymes, including cytochrome P450 (CYP), UDP-glucuronosyltransferase (UGT), and sulfotransferase 2A1 (SULT2A1), were analyzed by real-time reverse transcription polymerase chain reaction following 48-hour honokiol exposure in three independent cryopreserved human hepatocyte cultures...
2014: Drug Design, Development and Therapy
https://read.qxmd.com/read/25388680/genetic-markers-in-the-eet-metabolic-pathway-are-associated-with-outcomes-in-patients-with-aneurysmal-subarachnoid-hemorrhage
#34
JOURNAL ARTICLE
Mark K Donnelly, Yvette P Conley, Elizabeth A Crago, Dianxu Ren, Paula R Sherwood, Jeffery R Balzer, Samuel M Poloyac
Preclinical studies show that epoxyeicosatrienoic acids (EETs) regulate cerebrovascular tone and protect against cerebral ischemia. We investigated the relationship between polymorphic genes involved in EET biosynthesis/metabolism, cytochrome P450 (CYP) eicosanoid levels, and outcomes in 363 patients with aneurysmal subarachnoid hemorrhage (aSAH). Epoxyeicosatrienoic acids and dihydroxyeicosatetraenoic acid (DHET) cerebrospinal fluid (CSF) levels, as well as acute outcomes defined by delayed cerebral ischemia (DCI) or clinical neurologic deterioration (CND), were assessed over 14 days...
February 2015: Journal of Cerebral Blood Flow and Metabolism
https://read.qxmd.com/read/25363545/cytochrome-p450-single-nucleotide-polymorphisms-in-an-indigenous-tanzanian-population-a-concern-about-the-metabolism-of-artemisinin-based-combinations
#35
JOURNAL ARTICLE
Karol J Marwa, Theresa Schmidt, Maria Sjögren, Omary M S Minzi, Erasmus Kamugisha, Göte Swedberg
BACKGROUND: Artemisinin-based combinations currently recommended for treatment of uncomplicated Plasmodium falciparum malaria in many countries of sub-Saharan Africa are substrates of CYP enzymes. The cytochrome enzyme system is responsible for metabolism of about 80-90% of clinically used drugs. It is, therefore, important to obtain the pharmacogenetics of the population in the region with respect to these combinations and thereby enable practitioners to predict treatment outcomes. The aim of this study was to detect and determine allelic frequencies of CYP2C8*2, CYP2C8*3, CYP3A4*1B, CYP3A5*3 and CYP2B6*6 variant alleles in a Tanzanian indigenous population...
2014: Malaria Journal
https://read.qxmd.com/read/25311380/ppard-rs2016520-polymorphism-affects-repaglinide-response-in-chinese-han-patients-with-type%C3%A2-2-diabetes-mellitus
#36
RANDOMIZED CONTROLLED TRIAL
Jin-Fang Song, Tao Wang, Jing Zhu, Xue-Yan Zhou, Qian Lu, Hao Guo, Fan Zhang, Yan Wang, Wei Li, Dan-Dan Wang, Ya-Wen Cui, Dong-Mei Lv, Xiao-Xing Yin
Repaglinide is a short-acting insulin secretagogue, which often results in considerable interindividual variability in therapeutic efficacy when widely used in a clinical setting. Among various reasons under discussion is genetic polymorphism, especially the genes related to insulin secretion and resistance. Recent studies have described the importance of PPARD in regulating the secretion and resistance of insulin. However, little is known about the impacts of PPARD genetic polymorphism on the efficacy of repaglinide...
January 2015: Clinical and Experimental Pharmacology & Physiology
https://read.qxmd.com/read/25183026/absence-of-the-human-cyp2c8-3-allele-in-ugandan-children-exposed-to-plasmodium-falciparum-malaria
#37
JOURNAL ARTICLE
Giacomo Maria Paganotti, Valentina Cosentino, Gianluca Russo, Francesca Tabacchi, Silvia Gramolelli, Mario Coluzzi, Rita Romano
Study of host pharmacogenetics can improve our knowledge of mechanisms of drug resistance selection and spread. This issue has recently been addressed with respect to chloroquine and amodiaquine in malaria endemic areas of West and East Africa. Here we report, from surveys performed in two different areas of Uganda, that the human CYP2C8*3 allele, which had been reported to be strongly associated with parasite drug resistance in Zanzibar, is absent, being a marker of genetic admixture of the Zanzibari population with a Caucasoid component...
October 2014: Infection, Genetics and Evolution
https://read.qxmd.com/read/25177037/losartan-competitively-inhibits-cyp2c8-dependent-paclitaxel-metabolism-in-vitro
#38
JOURNAL ARTICLE
Yuji Mukai, Takaki Toda, Toru Hayakawa, Erik Eliasson, Anders Rane, Nobuo Inotsume
The present study aimed to characterize the inhibitory effects of losartan, an angiotensin II receptor blocker, on CYP2C8. Inhibition experiments were based on human lymphoblast-expressed recombinant CYP2C8 (rCYP2C8) and paclitaxel as a CYP2C8 substrate. The disappearance of paclitaxel (initial concentration: 7.5 µmol/L) was monitored over time at different concentrations of losartan (0, 100, 500 and 1000 µmol/L). For Dixon and Cornish-Bowden plots, various concentrations of losartan (final concentration: 0, 50, 100 and 250 µmol/L) and paclitaxel (final concentration: 3...
2014: Biological & Pharmaceutical Bulletin
https://read.qxmd.com/read/25160618/targeting-of-splice-variants-of-human-cytochrome-p450-2c8-cyp2c8-to-mitochondria-and-their-role-in-arachidonic-acid-metabolism-and-respiratory-dysfunction
#39
JOURNAL ARTICLE
Prachi Bajpai, Satish Srinivasan, Jyotirmoy Ghosh, Leslie D Nagy, Shouzou Wei, F Peter Guengerich, Narayan G Avadhani
In this study, we found that the full-length CYP2C8 (WT CYP2C8) and N-terminal truncated splice variant 3 (∼ 44-kDa mass) are localized in mitochondria in addition to the endoplasmic reticulum. Analysis of human livers showed that the mitochondrial levels of these two forms varied markedly. Molecular modeling based on the x-ray crystal structure coordinates of CYP2D6 and CYP2C8 showed that despite lacking the N-terminal 102 residues variant 3 possessed nearly complete substrate binding and heme binding pockets...
October 24, 2014: Journal of Biological Chemistry
https://read.qxmd.com/read/25145883/inhibitory-effects-of-hwang-ryun-hae-dok-tang-on-cytochrome-p450-in-human-liver-microsomes
#40
JOURNAL ARTICLE
Sang Yoon Lee, Himchan Jang, Ji-Yoon Lee, Jin Yeul Ma, Soo Jin Oh, Sang Kyum Kim
1. The herb-drug interaction potential of Hwang-Ryun-Hae-Dok-Tang (HR) extracts mediated by cytochrome P450 (CYP) inhibition was determined using human liver microsomes. 2. HR strongly inhibited CYP1A2 and moderately inhibited CYP2C19, CYP2D6, and CYP3A4 (testosterone) but not CYP2A6, CYP2B6, CYP2C8, CYP2C9, and CYP3A4 (midazolam). 3. The enzyme kinetic results suggest that CYP1A2 inhibition is competitively reversible (Ki, 13.4±1.8 μg/ml), and CYP2D6 inhibition is quasi-irreversible (KI, 0.234±0...
February 2015: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
keyword
keyword
26972
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.